HOOKIPA Pharma(US:HOOK)2021-06-25 18:49Immuno-Oncology Pipeline (HB-200 Program) - HB-200 monotherapy in L3+ head & neck cancer patients shows promising progression-free survival (PFS) data, better than 2L standard of care, and overall response rate (ORR) comparable to 2L PD1 inhibitor data[19] - In the ASCO data set (data cut-off Mar 31, 2021), out of 38 patients dosed, 18 patients were still on treatment[8] - Single dose of HB-201 or HB-202 drives robust T cell induction, with up to 8% of antigen-specific IFNg+ CD8+ T cells[10] - All patients treated with alternating HB-202/HB-201 IV showed increased CD8+ T cell levels, with an average increase of 6%, and a maximum of 40%[12] - 53% of patients had tumor regression with HB-201/HB-202 monotherapy[21] - The company plans to initiate Phase 2 studies in early 2022 for HB-200 in HPV16+ cancers, potentially registration-enabling[28] Infectious Diseases (HB-101 Program) - Approximately 20%-30% or ~25,000 solid organ transplant (SOT) recipients develop CMV disease annually worldwide[31] - In the U S, 20,000-30,000 birth defects occur annually due to CMV infection during pregnancy, representing 0.5%-1.0% of births[31] - HB-101 Phase 2 interim analysis shows that 3 doses induce 100% seroconversion at levels superior to 2 doses or placebo[38] - HB-101 Phase 2 interim analysis data in patients who obtained 3 doses shows a 48% reduction in CMV viremia, a 42% reduction in the required use of antivirals, and a 100% reduction in CMV disease[39] Financial Status - The company's cash position at the end of Q1 2021 was $128 million[2]